

Risk factors for *Clostridium difficile* infection in the community: a case-control study in patients in general practice, Denmark, 2009–2011

L. M. SØES^{1,2,3*}, H. M. HOLT⁴, B. BÖTTIGER^{5,6}, H. V. NIELSEN¹,
V. ANDREASEN³, M. KEMP⁴, K. E. P. OLSEN¹, S. ETHELBERG²
AND K. MØLBAK²

¹ Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark

² Department of Infectious Disease Epidemiology, Statens Serum Institut, Copenhagen, Denmark

³ Department of Science, Systems and Models, Roskilde University, Roskilde, Denmark

⁴ Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark

⁵ Department of Microbiological Diagnostics and Virology, Statens Serum Institut, Copenhagen, Denmark

⁶ Department of Microbiology, Skåne University Hospital, Malmö, Sweden

Received 6 April 2013; Final revision 23 August 2013; Accepted 30 August 2013;
first published online 27 September 2013

SUMMARY

To identify risk factors for *Clostridium difficile* infection (CDI) in Danish patients consulting general practice with gastrointestinal symptoms, a prospective matched case-control study was performed; cases ($N=259$) had positive cultures for toxigenic *C. difficile* and controls ($N=455$) negative cultures. Data were analysed by conditional logistic regression. In patients aged ≥ 2 years (138 cases), hospitalization [odds ratio (OR) 8.4, 95% confidence interval (CI) 3.1–23], consumption of beef (OR 5.5, 95% CI 2.0–15), phenoxymethylpenicillin (OR 15, 95% CI 2.7–82), dicloxacillin (OR 27, 95% CI 3.6–211), and extended spectrum penicillins (OR 9.2, 95% CI 1.9–45) were associated with CDI. In patients aged < 2 years none of these were associated with CDI, but in a subgroup analysis contact with animals was associated with CDI (OR 8.1, 95% CI 1.0–64). This study emphasizes narrow-spectrum penicillins, and suggests beef consumption, as risk factors for CDI in adults, and indicates a different epidemiology of CDI in infants.

Key words: Antibiotics, case-control study, children, community-associated *Clostridium difficile* infection, zoonoses.

INTRODUCTION

Clostridium difficile infection (CDI) is considered primarily a nosocomial infection with the major risk factors being advanced age, prior hospitalization, and use of antibiotics [1]. However, recent studies suggest that up to 30% of CDI cases may be community associated [2–4]. Wilcox *et al.* found that one

third of patients with community-associated CDI (CA-CDI) had not been to a hospital or treated with antibiotics prior to CDI [5]. Other determinants for *C. difficile* acquisition have been explored, including the possible role of zoonotic transmission [6]. PCR ribotype 078 is the predominant type found in pigs and calves, but other PCR ribotypes have also been reported in pigs and calves as well as in other animals. PCR ribotypes seem to vary between geographical areas and animal species [7, 8]. *C. difficile* has also been isolated from retail meat, although the rate varies considerably [6, 9, 10]. *C. difficile* has been described in pets, including cats and dogs, but the significance

* Author for correspondence: Ms. L. M. Søs, Department of Clinical Microbiology, Hvidovre Hospital, Kettegård Alle 30, DK-2650 Hvidovre, Denmark.
(Email: lillian_soees@dadlnet.dk)

of pets as a source of CDI remains unclear [7, 11, 12]. Both hospital- and community-based studies have found proton pump inhibitors (PPIs) as a risk factor for CDI [13–15], although other studies report contradictory results [16–18]. In one study contact with children aged <2 years was statistically significantly associated to CDI [5]. Little is known about the risk of secondary cases in household contacts of CDI cases. A recent study on this topic found the relative risk to be increased for a few months, but the absolute risk to be low [19]. Most studies on hospital-associated CDI as well as CA-CDI exclude children aged <2 years, leaving the question of risk factors in this group unexplored. The aim of the present study was to identify risk factors for CDI in the community, in children aged <2 years and individuals aged \geq 2 years, attending their general practitioner (GP) because of diarrhoea or other gastrointestinal symptoms.

METHODS

Study design

We conducted a prospective matched case-control study. The study included patients living in two parts of Denmark with both rural and urban areas and a total population of about 722 500. These two parts of the country were each served by a public clinical microbiological laboratory. All patients that had a faecal sample submitted for routine microbiological testing after attending their GP because of diarrhoea or other gastrointestinal symptoms, were consecutively included in the study when diagnosed. All stool samples were analysed for *C. difficile* irrespective of the requested diagnostic test of the GP. Cases were defined as patients with a faecal sample positive for toxigenic *C. difficile* by culture, i.e. patients with non-toxigenic *C. difficile* were excluded from the analyses. Individually matched controls were randomly selected in the laboratory database of patients with a faecal sample negative for *C. difficile* by culture, and within 2 months of laboratory receipt date of the case. Three controls per case were invited. The control group was selected to represent individuals comparable to CDI patients and with gastrointestinal complaints leading to the same diagnostic request. Only patients with no history of a laboratory-confirmed *C. difficile* infection in the last 6 months prior to the inclusion date were included. Cases and controls were matched by age, gender, and site for laboratory analyses of samples. For adults and children aged \geq 5 years,

the closest match within a time window of 2 years was used. For children aged <6 months, age matching was within a time window of 6 weeks. For children aged between 6 months and 4 years the time window was 5 months. The study period was from 24 August 2009 to 28 February 2011.

Microbiological analysis

Cycloserine cefoxitin fructose agar medium (SSI Diagnostica, Denmark) was used for isolation of *C. difficile* and agar plates were placed in an anaerobic atmosphere (86% N₂, 7% H₂, 7% CO₂) at 37 °C for 48 h.

Salmonella spp., *Campylobacter* spp., *Shigella* spp., *Yersinia enterocolitica*, *Aeromonas* spp., *Plesiomonas* spp., *Vibrio* spp. were isolated by standard culturing procedures. Enteropathogenic (EPEC), enterotoxigenic (ETEC), shiga toxin-producing (STEC), entero-invasive (EIEC) and attaching and effacing (A/EEC; no EPEC serotypes) *Escherichia coli* were identified by standard methods [20–22].

Gastroenteritis viruses were detected by real-time reverse transcription–polymerase chain reaction (rRT–PCR) using the OneStep Qiagen rRT–PCR kit (Qiagen Nordic, Denmark) and primers and probes for norovirus genogroups I and II [23], sapovirus [24], rotavirus [25], adenovirus [26], and astrovirus [27].

Giardia intestinalis, *Cryptosporidium* sp., *Entamoeba histolytica*, *E. dispar* and *Dientamoeba fragilis* were detected by real-time PCR [28].

The toxin gene profile of colonies of *C. difficile* was identified using a 5-plex PCR directed towards *tcdA*, *tcdB*, *cdtA*, *cdtB* and *16S* rDNA [29]. PCR ribotyping was performed, with minor modifications to the methods described previously by O'Neill *et al.* and Stubbs *et al.* [30, 31].

The bacteria (except for A/EEC), virus and parasites (except for *D. fragilis* and *E. dispar*) mentioned above were defined as generally accepted enteropathogens. *D. fragilis* and A/EEC were defined as candidate pathogens and *E. dispar* as non-pathogenic.

Case definitions

Diarrhoea was defined as >3 daily unformed stools (or for children using diapers more changes of diaper than usual) and the patient's own experience of going to the lavatory more often than usual. CDI cases were defined as patients with diarrhoea or other gastrointestinal symptoms and positive by culture for toxigenic *C. difficile*. Origin of CDI was classified

as CA-CDI in cases either without discharge from a healthcare facility (HCF) at least 12 weeks prior to onset of symptoms, or with onset of symptoms within 48 h following admission to a HCF and still without discharge from a HCF within 12 weeks before onset of symptoms. Healthcare-associated CDI (HCA-CDI) was defined as onset of symptoms at least 48 h after admission to a HCF or onset of symptoms within 4 weeks following discharge from a HCF. CDI of unknown origin was defined as onset of symptoms 4–12 weeks after discharge from a HCF. A HCF was defined as a hospital or a nursing home with skilled nursing care [32, 33].

Composition of questionnaire

Patients who fulfilled the inclusion criteria received a questionnaire by mail regarding clinical presentation of gastroenteritis and comorbidities, admission to hospital, contact with outpatient clinic and childbirth within the last 6 months prior to onset of symptoms, use of non-prescription medicine, food consumption and travelling abroad within 3 months prior to onset, contact with animals in the 2 weeks before infection, occupational exposures including working in hospitals, nursing homes, schools and nurseries, contact with children aged <2 years and contact with hospitalized individuals or nursing home residents.

The questions concerning underlying illness covered the following conditions: inflammatory bowel disease, diabetes mellitus, pre-existing renal failure and/or regular dialysis, cardiovascular disease, chronic obstructive pulmonary disease, metabolic disorders, rheumatoid arthritis, haematological malignancies, malignant solid tumours, and abdominal surgery within the 2 two months before infection.

Questions regarding food consumption included consumption of beef, pork, lamb, poultry, fish, eggs, cabbage, and other vegetables, fruit, soft drinks, sweets and pastry, milk products (both pasteurized and unpasteurized), and fermented milk products.

Contact with animals included contact with dogs, cats, guinea pigs, rabbits, horses, cattle, pigs, 'other domesticated animals', and 'other pets'.

Data on prescription medication for systemic use were obtained for each individual patient from the Danish Medicines Agency which maintains a national registry of all prescriptions. According to Dial *et al.* and Kelly the risk of CDI related to antibiotic exposure declines significantly after 6–8 weeks [34, 35]. On this basis antibiotics prescribed within 56 days

prior to onset of symptoms were included in the analysis. For all other drugs the prescription date was within 120 days prior to symptom onset.

Statistical analysis

The patients were divided into two age groups (<2 years and ≥ 2 years). All analyses were performed in these two age groups separately.

For matched univariable and multivariable analyses conditional logistic regression was used. Main analyses were performed with exposure variables obtained from the questionnaires and supplemented with an extended analysis of the additional data of prescription medication. Covariates statistically significant at the 90% level in the univariable analyses were included in the multivariable analysis. The outcome variables in the multivariable analysis of the medication data were adjusted for prior hospitalization and beef consumption. Test for interactions and multiple imputations of missing values were performed in the main effects model.

Additional analyses were performed in two different subgroups. In one subgroup analysis the definition of gastroenteritis was narrowed to include only cases and controls with diarrhoea. In the other subgroup analysis cases with *C. difficile* as the only enteropathogen in their faecal sample were included together with controls that had no generally accepted enteropathogens in their faecal sample.

Odds ratios (OR) were expressed with 95% confidence intervals (95% CI). All analyses were performed using SAS, version 9.1 (SAS Institute Inc., USA) and Stata v. 11 (StataCorp., USA).

Ethical considerations

The study was approved by the Danish Data Protection Agency (journal number: 2009-41-3534). Exemption for review by the ethical committee system was obtained from the Committee on Biomedical Research Ethics for Capital Region (protocol number: H-C-FSP-2009-006). A signed statement of consent to review data of prescription medication was obtained from all included patients or their parents if patients were aged <18 years.

RESULTS

Demographics and origin of infection

In total, 1559 patients were invited to participate. The response rate was 61% for *C. difficile*-positive

Table 1. Demographic characteristics, origin of infection, toxin gene profile of *Clostridium difficile* of patients attending general practice because of gastrointestinal symptoms, Denmark, 2009–2011

Variable	Age <2 years				Age ≥2 years			
	Cases		Controls		Cases		Controls	
	<i>n</i>	(%)	<i>n</i>	(%)	<i>n</i>	(%)	<i>n</i>	(%)
Demographic characteristic*								
Total number of patients	178		213		177		242	
Female sex	84	(47)	95	(45)	132	(75)	175	(72)
Median age (years)	0·95		1·06		50		50	
Age range (years)	0·30–1·98		0·25–1·98		2–94		2–90	
Interquartile range (years)	0·79–1·18		0·81–1·31		26–67		23–67	
Origin of infection								
Healthcare-associated CDI	0	(0)	—		31	(24)	—	
Community-associated CDI	110	(96)	—		90	(69)	—	
Unknown	5	(4)	—		9	(7)	—	
Information not available	6	(5)	—		8	(6)	—	
Toxin gene profile*								
A ⁺ B ⁺ CDT ⁺ †	12	(7)	—		35	(21)	—	
A ⁺ B ⁺ CDT ⁻ ‡	109	(62)	—		102	(60)	—	
A ⁻ B ⁺ CDT ⁻ §	0	(0)	—		1	(0·6)	—	
A ⁻ B ⁻ CDT ⁻ ¶	56	(32)	—		32	(19)	—	
Information not available	1	(0·5)	—		7	(4)	—	

CDI, *Clostridium difficile* infection.

* Includes both patients with non-toxicogenic and toxicogenic *C. difficile* strains.

† A⁺B⁺CDT⁺, strains with toxin gene profile: *tcdA+*, *tcdB+*, *cdtA+lcdtB+*.

‡ A⁺B⁺CDT⁻, strains with toxin gene profile: *tcdA+*, *tcdB+*, *cdtA-lcdtB-*.

§ A⁻B⁺CDT⁻, strains with toxin gene profile: *tcdA-*, *tcdB+*, *cdtA-lcdtB-*.

¶ A⁻B⁻CDT⁻, non-toxicogenic strains: *tcdA-*, *tcdB-*, *cdtA-lcdtB-*.

patients (patients with non-toxicogenic *C. difficile* and cases) and 46% for controls, i.e. 259 cases and 455 controls completed the questionnaire and were included in the study. Forty-seven per cent (121/259) of the cases were aged <2 years (Table 1). Age ranged from 13 weeks to 94 years. Table 1 shows the classification of the origin of infection. Following exclusion of non-toxicogenic strains, 110 (96%) of 115 patients aged <2 years were CA-CDI and none were HCA-CDI. In 130 patients aged ≥2 years 90 (69%) were CA-CDI and 31 (24%) were HCA-CDI.

Co-pathogens

Faecal samples from all 810 patients were accessible for analysis of enteropathogenic bacteria, 771 (95%) for viral and 765 (94%) for parasitic analysis. Table 2 gives the numbers of co-pathogens by age group. Concomitant microorganisms, considered as generally accepted gastrointestinal pathogens, were found in 62 (53%) cases and 120 (60%) controls

aged <2 years, with viruses accounting for the majority of co-pathogens, and in 30 (23%) cases and 60 (26%) controls aged ≥2 years.

Risk factor analysis

Antibiotic treatment and hospitalization prior to infection were statistically significantly associated with CDI in patients aged ≥2 years, but not in those aged <2 years (Table 3). Exclusion of children aged <2 years with a viral aetiology of diarrhoea did not result in any substantial difference in the model (data not shown).

The final multivariable model for risk factors in the group of patients aged ≥2 years contained hospitalization, use of antibiotics and consumption of beef at least weekly prior to infection (Table 4). When subdividing antibiotics, use of phenoxymethylpenicillin, dicloxacillin, and penicillins with extended spectrum remained statistically significant in the multivariable model (Table 5). No interactions between covariates

Table 2. Enteropathogens other than *Clostridium difficile* in the faecal sample in patients attending general practice because of gastrointestinal symptoms, Denmark, 2009–2011

	Age <2 years				Age ≥2 years			
	Cases (N=115–121)		Controls (N=198–213)		Cases (N=133–138)		Controls (N=222–242)	
Enteropathogens other than <i>C. difficile</i>	<i>n</i>	(%)	<i>n</i>	(%)	<i>n</i>	(%)	<i>n</i>	(%)
Generally accepted pathogens	62	(53)	120	(60)	30	(23)	60	(26)
Virus	58	(50)	105	(51)	13	(10)	27	(12)
Adenovirus	13	(11)	11	(5)	4	(3)	1	(0.5)
Astrovirus	10	(9)	87	(4)	2	(2)	1	(0.5)
Norovirus	20	(17)	51	(25)	6	(5)	15	(7)
Rotavirus	6	(5)	18	(9)	1	(0.8)	3	(1)
Sapovirus	9	(8)	17	(8)	0	(0)	7	(3)
Bacteria	28	(23)	53	(25)	20	(14)	32	(13)
<i>Salmonella</i> spp.	0	(0)	2	(0.9)	2	(1)	4	(2)
<i>Campylobacter</i> spp.	1	(0.8)	7	(3)	6	(4)	18	(7)
<i>Shigella</i> spp.	0	(0)	0	(0)	2	(1)	2	(0.8)
<i>Yersinia enterocolitica</i>	0	(0)	0	(0)	2	(1)	0	(0)
<i>Aeromonas</i> spp.	2	(2)	3	(1)	3	(2)	1	(0.4)
EPEC	3	(2)	10	(5)	0	(0)	0	(0)
ETEC	0	(0)	0	(0)	2	(1)	2	(0.8)
EIEC	0	(0)	0	(0)	0	(0)	0	(0)
A/EEC	22	(18)	36	(17)	3	(2)	9	(4)
Parasites	6	(5)	24	(12)	4	(3)	53	(24)
<i>Giardia duodenalis</i>	1	(0.9)	2	(1)	1	(0.8)	5	(2)
<i>Cryptosporidium</i> spp.	0	(0)	2	(1)	0	(0)	5	(2)
<i>Dientamoeba fragilis</i>	5	(4)	20	(10)	3	(2)	43	(19)
<i>Entamoeba dispar</i>	0	(0)	0	(0)	0	(0)	2	(0.9)
<i>Entamoeba histolytica</i>	0	(0)	0	(0)	0	(0)	1	(0.5)

EPEC, Enteropathogenic *Escherichia coli*; ETEC, enterotoxigenic *E. coli*; EIEC, enteroinvasive *E. coli*; A/EEC, attaching and effacing *E. coli*.

were found. Multiple imputations on missing variables were performed (about 10% of patients had missing information in one or more variable) in the main multivariable analysis based on questionnaire data as well as in the supplementary analysis based on medication data. In the supplementary analysis prior hospitalization and consumption of beef were included at first, in order to adjust for these variables and consumption of beef was subsequently excluded from the model because of a P value=0.059. Otherwise multiple imputations did not change the results in the multivariable analyses substantially and was therefore not used for the results given. Consumption of beef was still associated with CDI in patients aged ≥2 years, when multivariable analysis was performed in the two different subgroups counting (a) only patients with diarrhoea and (b) only patients with no generally accepted enteropathogens apart from *C. difficile* (OR 4.5, 95% CI 1.5–14 and OR 4.6,

95% CI 1.0–20, respectively). Forty different PCR ribotypes were represented in the group of beef consumers. Of these, besides type 078, there were also types 001, 012, 014/020/077, 015, 017, 023, 027, 029, 066, 070, 106/117, and 107 in addition to a series of minor PCR ribotypes.

Four per cent of cases aged ≥2 years received a fluoroquinolone before onset of symptoms. Only one case received moxifloxacin (Table 6). No statistically significant difference was found between cases and controls regarding use of fluoroquinolones. Clindamycin use prior to onset of symptoms was found in 6% of cases in contrast to controls, where none had clindamycin prescribed. Metronidazole was positively associated with CDI in the univariable analysis, but 13/17 (76%) of these patients also received another antibiotic with the most common indication for prescription being ‘infection’. PPIs prior to infection were not found to be associated with CDI (Table 6).

Table 3. Univariable matched analysis of risk factors for *Clostridium difficile* infection on the basis of selected variables from the questionnaire from patients attending general practice because of gastrointestinal symptoms, Denmark, 2009–2011

Variable*	Age < 2 years					Age ≥ 2 years						
	Cases (N = 106)		Controls (N = 145)		Cases vs. controls		Cases (N = 122)		Controls (N = 185)		Cases vs. controls	
	n/N	(%)	n/N	(%)	OR	95% CI	n/N	(%)	n/N	(%)	OR	95% CI
Comorbidity, patient reported	2/102	(2)	1/140	(1)	2.6	0.23–29	46/118	(39)	64/175	(37)	0.98	0.58–1.7
Medication												
Non-prescription antipropulsives	0	(0)	0	(0)	—	—	15/92	(16)	12/131	(9)	2.8	1.0–7.7
Antibiotic treatment†	19/105	(18)	19/139	(14)	1.5	0.68–3.1	58/121	(48)	23/175	(13)	6.7	3.4–13
Hospitalization	13/101	(13)	18/139	(13)	0.96	0.43–2.1	39/112	(35)	15/169	(9)	5.0	2.5–9.9
Contact with outpatient clinic	19/101	(19)	22/139	(16)	1.1	0.55–2.3	32/104	(31)	31/156	(20)	1.9	1.0–3.6
Childbirth	—	—	—	—	—	—	2/80	(3)	2/120	(2)	1.7	0.23–12
Food items consumed at least weekly												
Beef	71/102	(70)	97/138	(70)	0.95	0.48–1.9	97/114	(85)	124/174	(71)	2.7	1.4–5.4
Pork	73/102	(72)	100/138	(72)	1.0	0.53–2.0	98/112	(88)	132/171	(77)	2.3	1.1–4.7
Lamb	8/102	(8)	3/134	(2)	2.7	0.71–10	6/97	(6)	17/146	(12)	0.54	0.21–1.4
Poultry	71/102	(70)	86/137	(63)	1.3	0.72–2.3	94/115	(82)	129/172	(75)	1.5	0.83–2.8
Fish	58/102	(57)	85/136	(63)	0.70	0.38–1.3	84/113	(74)	118/169	(70)	1.2	0.71–2.1
Egg	32/102	(31)	47/137	(34)	0.92	0.50–1.7	74/113	(65)	116/172	(67)	0.96	0.59–1.6
Cabbage	49/99	(49)	66/135	(49)	1.1	0.62–1.8	64/112	(57)	110/172	(64)	0.72	0.43–1.2
Other vegetables	94/104	(90)	124/139	(89)	1.3	0.46–3.6	112/116	(97)	170/177	(96)	1.3	0.36–4.4
Fruit	99/105	(94)	134/142	(94)	1.2	0.28–5.1	102/116	(88)	164/178	(92)	0.57	0.23–1.4
Soft drinks	2/103	(2)	7/139	(5)	0.44	0.090–2.2	43/107	(40)	57/165	(35)	1.4	0.80–2.5
Sweets and pastry	9/103	(9)	25/140	(18)	0.40	0.17–0.95	67/113	(59)	103/173	(60)	1.04	0.61–1.8
Pasteurized milk	77/102	(75)	108/141	(77)	1.1	0.50–2.3	86/114	(75)	125/168	(74)	0.98	0.54–1.8
Milk, not pasteurized	1/95	(1)	4/126	(3)	0.39	0.042–3.6	1/93	(1)	3/130	(2)	0.39	0.040–3.8
Fermented milk products	51/102	(50)	69/139	(50)	1.1	0.64–1.9	78/113	(69)	114/171	(67)	1.1	0.64–1.8
Journey abroad	29/106	(27)	31/145	(21)	1.4	0.76–2.5	40/116	(34)	63/178	(35)	1.0	0.61–1.6
Contact with animals all together	74/104	(71)	90/143	(63)	1.5	0.86–2.6	75/114	(66)	111/174	(64)	1.2	0.67–2.0
Dog	54/90	(60)	61/119	(51)	1.4	0.82–2.4	60/109	(55)	83/162	(51)	1.3	0.74–2.2
Cat	30/86	(35)	41/117	(35)	1.0	0.57–1.9	39/108	(36)	65/164	(40)	0.94	0.55–1.6
Guinea pig	2/103	(2)	2/141	(1)	1.7	0.23–12	2/113	(2)	9/172	(5)	0.16	0.020–1.3
Rabbit	4/103	(4)	11/140	(8)	0.47	0.15–1.5	4/113	(4)	13/172	(8)	0.32	0.089–1.1
Horse	7/103	(7)	6/140	(4)	1.8	0.48–6.4	9/113	(8)	15/171	(9)	0.91	0.39–2.1
Cattle	2/103	(2)	4/141	(3)	0.75	0.12–4.7	0/113	(0)	5/172	(3)	—	—
Pig	2/104	(2)	2/143	(1)	1.4	0.19–10	1/113	(1)	2/172	(1)	0.50	0.045–5.5

OR, Odds ratio; CI, confidence interval. All cases with toxigenic *C. difficile*.

* Prior to infection.

† Data from Danish Medicines Agency.

Table 4. Multivariable matched analysis of risk factors for *Clostridium difficile* infection on the basis of data from the questionnaire. Patients aged ≥ 2 years attending general practice because of gastrointestinal symptoms, Denmark, 2009–2011

Variable*	OR	95% CI	P value
Antibiotic treatment	10	4.1–26	<0.0001
Hospitalization	8.4	3.1–23	<0.0001
Consumption of beef at least weekly	5.5	2.0–15	0.001

OR, Odds ratio; CI, confidence interval.

All cases with toxigenic *C. difficile*.

* Prior to infection.

Non-steroid anti-inflammatory drugs (NSAIDs) other than acetylsalicylic acid (ASA) were significantly associated with CDI in patients aged ≥ 2 years (Table 6). No association was found when ASA was included in NSAIDs (OR 0.7, 95% CI 0.3–1.4).

In the group of patients aged <2 years, only a few received prescription medication including antibiotics (Table 7).

Contact with animals was significantly associated with CDI in multivariable analysis (OR 8.1, 95% CI 1.0–64) when the group of patients aged <2 years, was set to include only cases and controls without other generally accepted enteropathogens than *C. difficile*.

Patients aged ≥ 15 years were asked about contact with children aged <2 years, this covariate was not associated with CDI (OR 0.5, 95% CI 0.2–1.4). Neither was contact with patients admitted to hospital (OR 0.5, 95% CI 0.1–2.3) or nursing home residents (OR 1.6, 95% CI 0.7–3.6) nor occupational exposure to hospital patients (OR 0.8, 95% CI 0.2–3.3) or nursing home residents/citizens receiving skilled nursing care in their own homes (OR 2.2, 95% CI 0.6–8.1).

Patients were asked about antibiotic use in the 3 months prior to onset of symptoms. When these data were combined with the data from the Danish Medicines Agency, 24% (31/131) of cases aged ≥ 2 years were neither admitted to hospital in the 6 months prior to onset of infection nor did they have any antibiotics in the 3 months prior to onset of symptoms. Notably, in the subgroup of cases aged ≥ 2 years with no other enteropathogens but *C. difficile* in the faecal sample (97 cases), this figure fell to 16%.

Of the 259 cases with toxigenic *C. difficile* and the 455 controls, information of stool consistency was

Table 5. Multivariable matched analysis of risk factors for *Clostridium difficile* infection on the basis of data of prescription medications. Patients aged ≥ 2 years attending general practice because of gastrointestinal symptoms, Denmark, 2009–2011

Variable*	OR	95% CI	P value
Penicillins with extended spectrum†	9.2	1.9–45	0.0065
Phenoxyethylpenicillin	15	2.7–82	0.0021
Dicloxacillin	27	3.6–211	0.0015

OR, Odds ratio; CI, confidence interval.

All cases with toxigenic *C. difficile*.

Variables adjusted for hospitalization and consumption of beef at least weekly.

* Prior to infection.

† Contains pivmecillinam, (piv)ampicillin, amoxicillin and amoxicillin/clavulanic acid.

accessible in 255 cases and 447 controls. Of these 12 (5%) cases and 39 (9%) controls did not fulfil the diarrhoea definition, but reported other gastrointestinal symptoms such as stomach ache, nausea, weight loss or bloody faeces. The results of the univariable analyses changed only slightly when these patients were excluded (data not shown) and they were therefore maintained in the main analyses.

DISCUSSION

Narrow-spectrum antibiotics, including phenoxyethylpenicillin and dicloxacillin were identified as risk factors for CDI. This is in line with two other studies that found aminopenicillins and penicillins to be associated with CDI [5, 14]. In a setting with preferential use of narrow-spectrum antibiotics, as for GPs in Denmark, it is important to be aware of the risk of CDI imposed by narrow-spectrum antibiotics. Conflicting results have been obtained in studies comparing patients with CA-CDI to individuals with or without diarrhoea and no CDI when analysing the role of PPIs as a risk factor [5, 14–15, 17, 36]. In our study 18% and 21% of cases and controls, respectively, had been treated with PPIs. Use of PPIs in the background population was 85/1000 inhabitants in Denmark in 2010. The high frequency of individuals taking PPIs in both cases and controls reflects that use of PPIs may increase the risk of acquiring CDI as well as gastroenteritis caused by other enteropathogens and is in line with a recent study by Bavishi & DuPont [18].

Table 6. Univariable matched analysis of prescription medications as risk factors for *Clostridium difficile* infection. Patients aged ≥ 2 years attending general practice because of gastrointestinal symptoms, Denmark, 2009–2011

Variable*	Cases (N=121)		Controls (N=175)		Cases vs. controls	
	n	(%)	n	(%)	OR	95% CI
Drugs for acid-related disorders	24	(20)	39	(22)	0.82	0.43–1.6
Magnesium oxide	4	(3)	1	(1)	4.7	0.52–43
Proton pump inhibitors	21	(17)	38	(22)	0.68	0.34–1.4
H ₂ receptor antagonists	1	(1)	0	(0)	—	—
Laxatives	3	(2)	4	(2)	0.91	0.20–4.1
Loperamid	1	(1)	0	(0)	—	—
ASA	11	(9)	18	(10)	0.74	0.32–1.7
NSAIDs	23	(19)	17	(10)	2.3	1.1–4.7
Systemic corticosteroids	4	(3)	2	(1)	2.3	0.41–13
All antimicrobials	58	(48)	23	(13)	6.7	3.4–13
Penicillins						
Penicillins with extended spectrum†	17	(14)	3	(2)	8.5	2.5–30
Phenoxymethylpenicillin	16	(13)	4	(2)	7.2	2.1–25
Dicloxacillin	19	(16)	2	(1)	14	3.3–62
Any cephalosporin	0	(0)	0	(0)	—	—
Clindamycin	7	(6)	0	(0)	—	—
Fluoroquinolones						
Ciprofloxacin	4	(3)	7	(4)	0.82	0.23–2.9
Moxifloxacin	1	(1)	0	(0)	—	—
All macrolides	7	(6)	1	(1)	7.8	0.95–64
Sulfonamides	0	(0)	2	(1)	—	—
Trimethoprim	0	(0)	1	(1)	—	—
Metronidazole	11	(9)	2	(1)	8.7	1.9–40
Opioids excluding codeine	21	(17)	10	(6)	4.1	1.7–9.8
Paracetamol	20	(17)	15	(9)	2.1	0.97–4.4
Insulins and analogues	2	(2)	1	(1)	3.2	0.29–37
Blood glucose-lowering drugs excluding insulins	2	(2)	8	(5)	0.32	0.064–1.6
Potassium chloride	11	(9)	2	(1)	7.0	1.5–32
Antithrombotic agents excluding ASA	11	(9)	5	(3)	3.0	1.0–8.9
Organic nitrates	2	(2)	2	(1)	1.4	0.19–10
Diuretics	22	(18)	20	(11)	1.6	0.81–3.2
Beta blocking agents	14	(12)	15	(9)	1.2	0.55–2.7
Calcium channel blockers	9	(7)	14	(8)	0.91	0.36–2.3
Agents acting on the rennin–angiotensin system	24	(20)	30	(17)	1.2	0.61–2.2
Lipid modifying agents	22	(18)	27	(15)	1.2	0.62–2.4
Contraceptives	16	(13)	22	(13)	1.1	0.45–2.8
Levothyroxine natrium	3	(2)	4	(2)	1.2	0.25–5.4
Drugs affecting bone structure and mineralization	4	(3)	7	(4)	0.77	0.22–2.7
Antimigraine preparations	4	(3)	2	(1)	6.4	0.68–61
Antiepileptics	6	(5)	6	(3)	2.0	0.54–7.3
Anxiolytics	4	(3)	3	(2)	2.3	0.41–13
Hypnotics and sedatives	11	(9)	15	(9)	0.96	0.37–2.5
Selective serotonin reuptake inhibitors	15	(12)	13	(7)	1.8	0.81–4.1

OR, Odds ratio; CI, confidence interval; ASA, acetylsalicylic acid; NSAIDs, non-steroid anti-inflammatory drugs.

All cases with toxigenic *C. difficile*.

* Antibiotics, except for trimethoprim, prescribed within 56 days prior to infection. Other drugs and trimethoprim prescribed within 120 days prior to infection.

† Contains pivmecillinam, (piv)ampicillin, amoxicillin and amoxicillin/clavulanic acid.

Table 7. Univariable matched analysis of prescription medications as risk factors for *Clostridium difficile* infection. Patients <2 years of age attending general practice because of gastrointestinal symptoms, Denmark, 2009–2011

Variable*	Cases (N=105)		Controls (N=139)		Cases vs. controls	
	n	(%)	n	(%)	OR	95% CI
Drugs for acid-related disorders						
Proton pump inhibitors	0	(0)	2	(1)	—	—
Laxatives	2	(2)	1	(1)	2.6	0.23–29
Loperamid	0	(0)	1	(1)	—	—
All antimicrobials	19	(18)	19	(14)	1.5	0.68–3.1
Penicillins						
Penicillins with extended spectrum†	10	(10)	13	(9)	1.1	0.43–2.9
Phenoxymethylpenicillin	8	(8)	7	(5)	1.4	0.50–4.0
Dicloxacillin	0	(0)	0	(0)	—	—
Any cephalosporin	0	(0)	0	(0)	—	—
Clindamycin	0	(0)	0	(0)	—	—
Fluoroquinolones						
Ciprofloxacin	1	(1)	0	(0)	—	—
Moxifloxacin	0	(0)	0	(0)	—	—
All macrolides	1	(1)	1	(1)	1.0	0.063–16
Sulfonamides	0	(0)	0	(0)	—	—
Trimethoprim	0	(0)	1	(1)	—	—
Metronidazole	1	(1)	1	(1)	1.0	0.063–16

OR, Odds ratio; CI, confidence interval.

All cases with toxigenic *C. difficile*.

* Antibiotics, except for trimethoprim, prescribed within 56 days prior to infection. Other drugs and trimethoprim prescribed within 120 days prior to infection.

† Contains pivmecillinam, (piv)ampicillin, amoxicillin and amoxicillin/clavulanic acid.

We found a marked difference in risk factor profile between cases aged <2 years and older cases. Hospitalization and use of antibiotics prior to onset of symptoms were associated with CDI in individuals aged ≥ 2 years, but not in children aged <2 years. The existence of CDI in early childhood is under debate, and on this basis most studies exclude children aged <2 years. Many investigators regard toxigenic *C. difficile* as non-pathogenic in children aged <2 years, and high carriage rates are described in asymptomatic neonates [37–39]. On the other hand, other studies have reported CDI in children aged <2 years [40–42] and therefore we decided to include this age group in our investigation. In contrast with older patients, we could not identify any meaningful predictors of CDI in the main analyses in this age group which indicates that the epidemiology of CDI in young children is distinct from individuals aged ≥ 2 years. It might be considered whether the observed differences in risk factors for CDI between children aged <2 years and older patients aged ≥ 2 years is due to a higher frequency of viral

infections in the former group. However, excluding cases with concomitant virus from the analyses did not change results (data not shown), and the absence of risk factors cannot be ascribed to differences in frequencies of viral infections. Although, in a subgroup of patients aged <2 years, including only cases and controls without other generally accepted enteropathogens than *C. difficile* contact with animals was significantly associated with CDI in multivariable analysis. The finding could indicate contact with animals as a risk factor for CDI or for colonization with *C. difficile*. It can be speculated that infants' unreservedly close contact with animals is the reason for this association in just this age group and that exclusion of cases and controls with other enteropathogens than *C. difficile* in the faecal sample tends to strengthen the association since other enteropathogens, e.g. *Campylobacter jejuni* isolates from humans and pets have been demonstrated to be closely related by molecular typing [43]. However, our result is hard to interpret since many different animals (both household pets and domestic animals) were included in

the analysis. *C. difficile* has been described in household pets, including cats and dogs. Borriello *et al.* found that *C. difficile* was present in 23% of stool samples from the household pets investigated, including 49 dogs, 19 cats and one duck. Most strains were non-toxicogenic [11]. Weese *et al.* found no evidence of dogs being a significant source of household *C. difficile* contamination [12]. More studies are needed to outline this topic.

Contact with children aged <2 years has been significantly associated with CDI in one study [5]. Our study could not confirm this finding. Furthermore, we found no association between exposure to patients admitted to hospital or nursing home residents and CDI.

Consumption of beef was significantly associated with CDI in patients aged ≥ 2 years. *C. difficile* can be detected in various farm animals including calves and pigs and it has been suggested that CDI could be a zoonosis [6, 44]. The bacterium has also been isolated from retail meat, although the rate varies considerably [6, 9–10]. PCR ribotype 078 is the predominant type in pigs and calves in some studies, but PCR ribotypes seem to vary between geographical areas and animal species [7, 8, 44, 45]. PCR ribotype 078 is also found in humans with CDI [46]. We found PCR ribotype 078 in cases reporting beef consumption (four of the five type 078 cases consumed beef). However, many other PCR ribotypes of *C. difficile* were present in beef eaters as well, and distinct PCR ribotypes did not indicate beef *per se* as a source of infection. Multiple imputations on missing variables formally resulted in exclusion of beef from the model in the supplementary analysis based on medication data ($P=0.059$), although it is possible that the association would have been statistically significant if more patients had been included in the study. The association of beef consumption with CDI suggests that a proportion of CDI cases are associated with beef consumption. Alternatively, theoretically the selection of controls with non-CDI diarrhoea may have introduced a bias if other food items than beef, e.g. poultry or pork caused the diarrhoea of the controls and they therefore *a priori* had a lower consumption of beef than the cases and the background population. However, we do not believe that this would explain the association noted here and further studies are needed to clarify whether there is a causal relationship between beef consumption and CDI.

In the group of cases aged ≥ 2 years, 24% were neither admitted to hospital in the 6 months prior

to onset of infection nor were they prescribed antibiotics in the 3 months prior to onset of symptoms when prescription medication data from the Danish Medicines Agency were combined with data from the questionnaire. The percentage fell to 16% when only cases with *C. difficile* as the only pathogen in the faecal sample were included. In a study by Wilcox *et al.*, 35% of CDI cases neither had exposure to antibiotics nor hospitalization 4 weeks and 6 months prior to infection, respectively. Faecal samples were examined for *Salmonella* spp., *Shigella* spp., *Campylobacter* spp., and *E. coli* O157, but for no other diarrhoeagenic *E. coli* or viruses [5]. In our study viral and parasitic analyses were performed in addition to analysis for bacterial enteropathogens. The more extended examination for enteropathogens together with the longer period of exposure to antibiotics (3 months vs. 4 weeks) prior to infection could be one of the explanations for the differences in the percentage of cases without hospitalization and use of antibiotics prior to infection in the two studies.

We found 69% of cases aged ≥ 2 years to be CA-CDI. Only CDI patients who had a faecal sample submitted by their GP were included in the study. Therefore, the CDI patients in the community who were admitted directly to hospital without consulting their GP, e.g. because of severe diarrhoea, are missing from the study, leading to a possible lower proportion of community-associated cases in the study.

The study has some limitations. A matched case-control study was chosen to take possible confounding into account. The resulting loss of power may have masked other possible significant associations. The choice of gastrointestinal patients as control group was chosen to better detect *C. difficile*-specific predictors, but this may, on the other hand, have obscured risk factors for CDI that were in common with other infectious gastrointestinal diseases; thus it is possible that the role of PPIs may have been masked, as this will also be a risk factor for other bacterial gastrointestinal infections. The response rate was 61% and 46% for *C. difficile*-positive patients and controls, respectively. This should be borne in mind in terms of generalizability of the study. Still, the study population was $\sim 722\,500$ ($\sim 13\%$ of total population in Denmark) and included patients living in both rural and urban areas. Non-responder cases had a higher median age (59 vs. 50 years) and a higher 30-day mortality (3.6% vs. null per cent) compared to responders, indicating that non-responder cases might have had more severe CDI and/or a higher frequency of

comorbidities compared to responders. For controls 30-day mortality was null per cent and 0.4% for responders and non-responders, respectively.

To conclude, our results emphasize prior hospitalization and intake of narrow-spectrum antibiotics as important predictors of CDI in the community in individuals aged ≥ 2 years, but not in children aged < 2 years, and suggest that a proportion of CDI cases are associated with other risk factors. The study indicates beef consumption and infants' contacts with animals as other possible risk factors. Narrow-spectrum antibiotics are the drug of choice of GPs in Denmark. This study emphasizes the importance of not neglecting the risk of CDI imposed by these antibiotics not only in the hospital setting, but also in the community.

ACKNOWLEDGEMENTS

We thank all laboratory technicians that participated in stool sample analyses at Statens Serum Institut, Copenhagen and Odense University Hospital, Odense.

DECLARATION OF INTEREST

None.

REFERENCES

1. **Bartlett JG**. Historical perspectives on studies of *Clostridium difficile* and *C. difficile* infection. *Clinical Infectious Diseases* 2008; **46**: S4–S11.
2. **Karlstrom O, et al.** A prospective nationwide study of *Clostridium difficile*-associated diarrhea in Sweden. The Swedish *C. difficile* Study Group. *Clinical Infectious Diseases* 1998; **26**: 141–145.
3. **Noren T, et al.** Molecular epidemiology of hospital-associated and community-acquired *Clostridium difficile* infection in a Swedish county. *Journal of Clinical Microbiology* 2004; **42**: 3635–3643.
4. **Søes LM, et al.** Clinical features of *Clostridium difficile* infection and molecular characterization of the isolated strains in a cohort of Danish hospitalized patients. *European Journal of Clinical Microbiology and Infectious Diseases* 2012; **31**: 185–192.
5. **Wilcox MH, et al.** A case-control study of community-associated *Clostridium difficile* infection. *Journal of Antimicrobial Chemotherapy* 2008; **62**: 388–396.
6. **Gould LH, Limbago B.** Food Safety: *Clostridium difficile* in food and domestic animals: a new food-borne pathogen? *Clinical Infectious Diseases* 2010; **51**: 577–582.
7. **Keessen EC, Gaastra W, Lipman LJA.** *Clostridium difficile* infection in humans and animals, differences and similarities. *Veterinary Microbiology* 2011; **153**: 205–217.
8. **Rodriguez-Palacios A, et al.** *Clostridium difficile* PCR ribotypes in calves, Canada. *Emerging Infectious Diseases* 2006; **12**: 1730–1736.
9. **Rodriguez-Palacios A, et al.** *Clostridium difficile* in retail ground meat, Canada. *Emerging Infectious Diseases* 2007; **13**: 485–487.
10. **Von Abercron SM, et al.** Low occurrence of *Clostridium difficile* in retail ground meat in Sweden. *Journal of Food Protection* 2009; **72**: 1732–1734.
11. **Borriello SP, et al.** Household pets as a potential reservoir for *Clostridium difficile* infection. *Journal of Clinical Pathology* 1983; **36**: 84–87.
12. **Weese JS, et al.** Evaluation of *Clostridium difficile* in dogs and the household environment. *Epidemiology and Infection* 2010; **138**: 1100–1104.
13. **Yearsley KA, et al.** Proton pump inhibitor therapy is a risk factor for *Clostridium difficile*-associated diarrhoea. *Alimentary Pharmacology & Therapeutics* 2006; **24**: 613–619.
14. **Kuntz J, et al.** Incidence of and Risk Factors for Community-associated *Clostridium difficile* Infection: a nested case-control study. *BMC Infectious Diseases* 2011; **11**: 194.
15. **Dial S, et al.** Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *Journal of American Medical Association* 2005; **294**: 2989–2995.
16. **Hensgens MPM, et al.** *Clostridium difficile* infection in an endemic setting in the Netherlands. *European Journal of Clinical Microbiology and Infectious Diseases* 2011; **30**: 587–593.
17. **Naggie S, et al.** A Case-control Study of Community-associated *Clostridium difficile* Infection: No Role for Proton Pump Inhibitors. *American Journal of Medicine* 2011; **124**: 276.
18. **Bavishi C, DuPont HL.** Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. *Alimentary Pharmacology & Therapeutics* 2011; **34**: 1269–1281.
19. **Pépin J, Gonzales M, Valiquette L.** Risk of secondary cases of *Clostridium difficile* infection among household contacts of index cases. *Journal of Infection* 2012; **64**: 387–390.
20. **Blom M, et al.** Evaluation of Statens Serum Institut enteric medium for detection of enteric pathogens. *Journal of Clinical Microbiology* 1999; **37**: 2312–2316.
21. **Hutchinson DN, Bolton FJ.** Improved blood free selective medium for the isolation of *Campylobacter jejuni* from faecal specimens. *Journal of Clinical Pathology* 1984; **37**: 956–957.
22. **Persson S, et al.** A method for fast and simple detection of major diarrhoeagenic *Escherichia coli* in the routine diagnostic laboratory. *Clinical Microbiology and Infection* 2007; **13**: 516–524.
23. **Kageyama T, et al.** Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. *Journal of Clinical Microbiology* 2003; **41**: 1548–1557.

24. **Johnsen CK, Midgley S, Böttiger B.** Genetic diversity of sapovirus infections in Danish children 2005–2007. *Journal of Clinical Virology* 2009; **46**: 265–269.
25. **Pang XL, et al.** Increased detection of rotavirus using a real time reverse transcription-polymerase chain reaction (RT-PCR) assay in stool specimens from children with diarrhea. *Journal of Medical Virology* 2004; **72**: 496–501.
26. **Logan C, O’Leary JJ, O’Sullivan N.** Real-time reverse transcription-PCR for detection of rotavirus and adenovirus as causative agents of acute viral gastroenteritis in children. *Journal of Clinical Microbiology* 2006; **44**: 3189–3195.
27. **Logan C, O’Leary JJ, O’Sullivan N.** Real-time reverse transcription PCR detection of norovirus, sapovirus and astrovirus as causative agents of acute viral gastroenteritis. *Journal of Virological Methods* 2007; **146**: 36–44.
28. **Stensvold CR, Nielsen HV.** Comparison of microscopy and PCR for detection of intestinal parasites in Danish patients supports an incentive for molecular screening platforms. *Journal of Clinical Microbiology* 2012; **50**: 540–541.
29. **Persson S, Torpdahl M, Olsen KE.** New multiplex PCR method for the detection of *Clostridium difficile* toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. *Clinical Microbiology and Infection* 2008; **14**: 1057–1064.
30. **O’Neill GL, et al.** Modification of a PCR Ribotyping Method for Application as a Routine Typing Scheme for *Clostridium difficile*. *Anaerobe* 1996; **2**: 205–209.
31. **Stubbs SL, et al.** PCR targeted to the 16S-23S rRNA gene intergenic spacer region of *Clostridium difficile* and construction of a library consisting of 116 different PCR ribotypes. *Journal of Clinical Microbiology* 1999; **37**: 461–463.
32. **Kuijper EJ, Coignard B, Tull P.** Emergence of *Clostridium difficile*-associated disease in North America and Europe. *Clinical Microbiology and Infection* 2006; **12** (Suppl. 6): 2–18.
33. **McDonald LC, et al.** Recommendations for surveillance of *Clostridium difficile*-associated disease. *Infection Control and Hospital Epidemiology* 2007; **28**: 140–145.
34. **Dial S, et al.** Patterns of antibiotic use and risk of hospital admission because of *Clostridium difficile* infection. *Canadian Medical Association Journal* 2008; **179**: 767–772.
35. **Kelly CP.** A 76-year-old man with recurrent *Clostridium difficile*-associated diarrhea: review of *C. difficile* infection. *Journal of American Medical Association* 2009; **301**: 954–962.
36. **Kutty PK, et al.** Risk factors for and estimated incidence of community-associated *Clostridium difficile* infection, North Carolina, USA. *Emerging Infectious Diseases* 2010; **16**: 197–204.
37. **Holst E, Helin I, Mardh PA.** Recovery of *Clostridium difficile* from children. *Scandinavian Journal of Infectious Diseases* 1981; **13**: 41–45.
38. **Vesikari T, et al.** *Clostridium difficile* in young children. Association with antibiotic usage. *Acta Paediatrica Scandinavica* 1984; **73**: 86–91.
39. **Viscidi R, Willey S, Bartlett JG.** Isolation rates and toxigenic potential of *Clostridium difficile* isolates from various patient populations. *Gastroenterology* 1981; **81**: 5–9.
40. **Kim J, et al.** Epidemiological features of *Clostridium difficile*-associated disease among inpatients at children’s hospitals in the United States, 2001–2006. *Pediatrics* 2008; **122**: 1266–1270.
41. **Zilberberg MD, Tillotson GS, McDonald C.** *Clostridium difficile* infections among hospitalized children, United States, 1997–2006. *Emerging Infectious Diseases* 2010; **16**: 604–609.
42. **Turco R, et al.** Proton pump inhibitors as a risk factor for paediatric *Clostridium difficile* infection. *Alimentary Pharmacology and Therapeutics* 2010; **31**: 754–759.
43. **Damborg P, et al.** Occurrence of *Campylobacter jejuni* in pets living with human patients infected with *C. jejuni*. *Journal of Clinical Microbiology* 2004; **42**: 1363–1364.
44. **Rupnik M.** *Clostridium difficile*: (re)emergence of zoonotic potential. *Clinical Infectious Diseases* 2010; **51**: 583–584.
45. **Keel K, et al.** Prevalence of PCR ribotypes among *Clostridium difficile* isolates from pigs, calves, and other species. *Journal of Clinical Microbiology* 2007; **45**: 1963–1964.
46. **Goorhuis A, et al.** Emergence of *Clostridium difficile* infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. *Clinical Infectious Diseases* 2008; **47**: 1162–1170.